SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.

SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.